Saol Therapeutics News

Saol Therapeutics Announces Topline Data from the SL-1002 RAISE Limb Spasticity Trial to be Presented at Spasticity X – the First International Spasticity Symposium – on October 25, 2024

ROSWELL, Ga, DUBLIN and HAMILTON, Bermuda, October 22, 2024 / -- Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, announced today that topline safety and efficacy data for the SL-1002 RAISE Limb Spasticity Trial (NCT05311215) will be presented at the Spasticity X Symposium in Houston, TX on October 25, 2024.

Presentation Title: Results of the Phase II Study of SL-1002 in Limb Spasticity
Presentation Date and Time: Friday, October 25, from 4:10-4:30pm CST
Presenters:

Sheng Li, MD, PhD, Houston, TX 

  • Professor, Department of Physical Medicine and Rehabilitation (PM&R) at McGovern Medical School at UTHealth
  • Attending Physician, TIRR Memorial Herman
  • Director, Stroke Rehabilitation and Recovery Research, TIRR Memorial Hermann Hospital
  • Director, Neurorehabilitation Research Laboratory and UTHealth NeuroRecovery Research Center at TIRR Memorial Hermann

Gerard Francisco, MD, Houston, TX 

  • The Wulfe Family Chair Of Physical Medicine And Rehabilitation, McGovern Medical School - UTHealth
  • Chairman And Professor (With Tenure), Distinguished Teaching Professor, UT Systems
  • Chief Medical Officer And Clinical Scientist, TIRR Memorial Hermann

“We are very pleased to have the SL-1002 RAISE Limb Spasticity Trial topline data presented at Spasticity X,” said Saol Therapeutics CEO Dave Penake.  “This symposium will bring together some of the world’s leading experts in spasticity management, and we’re excited to share the progress of our SL-1002 program with them in Houston.”

SL-1002 is a novel, chemoneurolytic injection, that utilizes Saol’s proprietary CYCLOPHLEXTM technology.

The RAISE Limb Spasticity Trial is a randomized (3:1), double-blind, vehicle-controlled single ascending dose escalation study intended to assess the safety, pharmacokinetics, and efficacy of a single treatment of SL-1002 in patients with mild to severe limb spasticity. Following randomization, the study period lasted 26 weeks.  The primary endpoint is the overall safety profile of a single treatment exposure of SL-1002 in comparison to vehicle.

 

About RAISE Limb Spasticity Trial

The RAISE Limb Spasticity Trial is a Randomized double-blind, vehicle-controlled, single AscendIng dose escalation study to assess the Safety, Pharmacokinetics and Efficacy of SL-1002 in adult patients with limb spasticity.  (NCT05311215).

 

About COMPASS Osteoarthritis Knee Pain Trial

In addition to the RAISE Spasticity Trial, SL-1002 is also being investigated for the treatment of pain related to osteoarthritis of the knee.  The COMPASS Osteoarthritis Knee Pain Trial is a multicenter, randomized, double-blind, vehicle-COntrolled, single-ascending dose escalation study to assess the safety and efficacy of SL-1002 injectable for treatMent of PAin aSSociated with OsteoArthritis of the knee.  (NCT05470608).

 

About SL-1002

SL-1002 is a novel, chemoneurolytic injection, that utilizes Saol’s proprietary CYCLOPHLEXTM technology. It is currently being developed for the treatment of chronic knee pain related to osteoarthritis and limb spasticity, both in the adult population (18+) in the United States.

 

About Saol Therapeutics

Saol Therapeutics (pronounced "Sail") is a privately held, clinical-stage, pharmaceutical company with operations in Roswell, GA, Dublin, Ireland, and Hamilton, Bermuda.  Saol is focused on development activity in CNS disorders such as spasticity and pain management, and orphan diseases.  Saol is committed to providing and advancing therapeutic options for patients and the physicians treating these populations.  For more information, visit www.saolrx.com.